Triple Drug Therapy for Thyroid Cancer
Trial Summary
Do I need to stop my current medications to join the trial?
The trial protocol does not specify if you need to stop taking your current medications. However, if you are HIV-positive and on antiretroviral therapy, you are not eligible to participate.
What data supports the effectiveness of the drug combination used in the Triple Drug Therapy for Thyroid Cancer?
Is the triple drug therapy for thyroid cancer safe?
The combination of dabrafenib and trametinib has been generally well tolerated in patients with thyroid cancer, with common side effects including fatigue, fever, and nausea. However, there have been rare cases of serious neurological side effects like Guillain-Barre syndrome, which is important for patients and doctors to be aware of.46789
What makes the triple drug therapy for thyroid cancer unique?
The triple drug therapy for thyroid cancer is unique because it combines Cemiplimab, Dabrafenib, and Trametinib, which target different pathways involved in cancer growth. Cemiplimab is an immunotherapy that helps the immune system attack cancer cells, while Dabrafenib and Trametinib target specific proteins involved in cell growth, making this combination potentially more effective than using each drug alone.1011121314
What is the purpose of this trial?
This study is being done to see if adding the study drug, cemiplimab, to the standard therapy with dabrafenib and trametinib is an effective treatment against anaplastic thyroid cancer.
Research Team
Eric Sherman, MD
Principal Investigator
Memorial Sloan Kettering Cancer Center
Eligibility Criteria
This trial is for adults with anaplastic thyroid cancer that has a specific BRAF-V600E mutation. It's open to those who haven't been cured by surgery, can undergo biopsies, and have measurable disease. Participants need normal heart function and organ health, must not be pregnant, agree to use contraception, and be able to take oral meds.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive cemiplimab in combination with dabrafenib and trametinib
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Cemiplimab
- Dabrafenib
- Trametinib
Cemiplimab is already approved in European Union, United States, Canada, Brazil for the following indications:
- Cutaneous squamous cell carcinoma (CSCC)
- Non-small cell lung cancer (NSCLC)
- Cutaneous squamous cell carcinoma (CSCC)
- Basal cell carcinoma (BCC)
- Non-small cell lung cancer (NSCLC)
- Cutaneous squamous cell carcinoma (CSCC)
- Non-small cell lung cancer (NSCLC)
- Cutaneous squamous cell carcinoma (CSCC)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Memorial Sloan Kettering Cancer Center
Lead Sponsor